Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.06

Galectin Therapeutics reported $25.6M in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Galectin Therapeutics USD 25.6M 2.04M Jun/2024
Gilead Sciences USD 7.56B 234M Dec/2025
Immunic USD 186.63M 171.15M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Merck USD 5.33B 9.24B Mar/2026